Additional exploratory analyses showed a trend toward higher prevalence of TP53 pathway alterations in Hispanic/Latino EOCRC patients (OR = 2.13, p = 0.084) and identified sex-based disparities in treatment, with women being less likely than men to receive FOLFOX (OR = 0.845, p = 0.0138).
While the difference did not reach statistical significance, the analysis demonstrates the platform’s ability to perform subsite-specific cohort filtering and comparative survival modeling in the context of defined pathway alterations—supporting granular, hypothesis-generating investigations into the anatomical heterogeneity of CRC outcomes. 3.5.